A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Phase 3 Active not recruiting 20284 enrolled Janssen Research & Development, LLC Bristol-Myers Squibb · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Timeline

Start: 2023-04-11
Primary completion: 2026-10-31
Completion: 2026-10-31

Publications

Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, Lam CSP; LIBREXIA AF Trial Investigators and Committees. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Nov;277:145-158. doi: 10.1016/j.ahj.2024.08.011. Epub 2024 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Apixaban	Small molecule	2.5 mg	Oral
Comparator	Apixaban	Small molecule	5 mg	Oral
Subject	Milvexian	Small molecule	100 mg	Oral

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Summary

Timeline

Publications

Drugs

Indications